Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator
The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.
You may also be interested in...
News We’re Watching: Activist Investor Causes Kerfuffle At Nevro, Lifespin Launches Antibiotic Dx, And More
Medtech Insight's News We're Watching highlights medtech industry news developments that you may have missed over the last few weeks. Last week, EndoQuest closed a $42m round to support its endoluminal surgery system, Intuitive Ventures closed a $150m round, Noah Surgical announced the first biopsy procedures with its Galaxy technology in Asia, the FDA cleared Smileyscope's VR system to reduce needle anxiety, and Guardant will collaborate with Cancer Research UK.
Medicare’s recent expansion of coverage for spinal cord stimulation therapy to treat diabetic peripheral neuropathy could mean relief for some 11 million Americans. Executives from Redwood City, CA device maker Nevro talked to Medtech Insight about the expansion and what it means for patients who use their technology.
Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s new labeling for Abbott’s spinal cord stimulation devices that includes non-surgical back pain.